Literature DB >> 33818614

Tocilizumab in Treatment for Patients With COVID-19.

Chengliang Yang1, Mingyao Liu1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33818614     DOI： 10.1001/jamainternmed.2021.0392

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  2 in total

Review 1.  Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19.

Authors:  Elizabeth Leung; Ryan L Crass; Sarah C J Jorgensen; Sumit Raybardhan; Bradley J Langford; W Justin Moore; Nathaniel J Rhodes
Journal:  Clin Pharmacokinet       Date:  2021-12-11       Impact factor: 6.447

2.  Tocilizumab for the treatment of non-critical COVID-19 pneumonia: an overview of the rationale and clinical evidence to date.

Authors:  Grace Kenny; Patrick W G Mallon
Journal:  Expert Rev Clin Pharmacol       Date:  2021-07-26       Impact factor: 5.045
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.